These included enhanced infiltration of CD8+ T cells, improved immune memory, and complete tumor rejection in rechallenge models, further supporting the notion that ICD serves not only as a cytotoxic endpoint but also as a powerful immunological primer. The gene discussed is CD8A; the disease is neoplasm.